SimianX AI LogoSimianX AI

Record mula sa primary source

Decision-gradePagbabago sa trial registry

Daré Bioscience: pangalawang positibong pagsusuri ng DSMB sa Ovaprene Phase 3

Natapos ng independiyenteng DSMB ang pangalawang nakaplanong interim analysis ng patuloy na Phase 3 trial at muling inirerekomenda na ipagpatuloy ang pag-aaral nang walang pagbabago. Sakop ng pagsusuri ang 339 na paksa at 1,789 menstrual cycle; walang bagong safety signal na lumitaw at ang naobserbahang pregnancy rate ay nanatiling pare-pareho sa mga naunang inaasahan. Inaasahan na ngayon ng Daré na maabot ang 2,500-cycle enrollment target sa 2026, na naglalagay sa primary endpoint analysis para sa 2027.

Mahahalagang fact

Na-file
May 14, 2026, 08:01 PM
Kaganapan
Pagbabago sa trial registry
Direksyon
Positibo
Kumpanya
DAREDare Bioscience, Inc.
Asset
Flora Sync LF5
Pinagmulan
SEC 8-K
Kumpiyansa
May source
Target na bilang ng siklo
2,500
rate ng pagbubuntis
9%
cycles na nasuri
1,789
subjects na nasuri
339

Sipi mula sa source

EX-99.1 2 a260514q12026earningsupd.htm EX-99.1 a260514q12026earningsupd Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update Your publication date and time will appear here. | Source: Daré Bioscience, Inc. Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women’s Health Week. Conference Call and Webcast Today at 4:30 p.m. ET “We are hosting our financial results and business update call from New York, in the middle of National Women’s Health Week,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Biosc

SEC 8-K

Higit pa tungkol sa asset na ito

Kapansin-pansin
Ago 13, 2026
08:02 PM
DAREDare Bioscience, Inc.

Iniulat ng Daré Bioscience ang mga resulta ng Q2 2026 at inilunsad ang Flora Sync LF5

Presentasyon sa kumperensyaSEC 8-K
Decision-grade
May 12, 2026
12:00 PM
DAREDare Bioscience, Inc.

Daré Bioscience: Positibong interim na resulta ng Phase 3 para sa Ovaprene

Topline na resultaPress release ng kumpanyaBuksan ang record